Active Behavior of Triple-Negative Breast Cancer With Adipose Tissue Invasion: A Single Center and Retrospective Review

doi:10.21203/rs.3.rs-138480/v1

Download PDF

Research article

Active Behavior of Triple-Negative Breast Cancer With Adipose Tissue Invasion: A Single Center and Retrospective Review

https://doi.org/10.21203/rs.3.rs-138480/v1

This work is licensed under a CC BY 4.0 License

Journal Publication

published 20 Apr, 2021

Read the published version in BMC Cancer →

You are reading this latest preprint version

Background

Interactions between adipocyte and breast cancer (BC) cells have yet to be fully elucidated. Here we investigated the prognostic impact of marginal adipose tissue invasion in both luminal breast cancer (HR+/HER2-) and triple-negative breast cancer (TNBC) (HR-/HER2-).

Methods

A total of 735 patients with early-stage invasive BC (1999-2014) were retrospectively registered. Median length of patient follow-up was 8.9 years. Survival curves were calculated using a Kaplan-Meier cumulative survival plot. The prognostic difference between two groups were assessed by the univariate Cox-proportional hazard regression model.

Results

Patients with adipose tissue invasion (n = 614) had a significantly poorer prognosis than those without adipose tissue invasion (n = 121) in overall survival (OS) (hazard ratio, 2.1; 95% Confidence interval [CI], 1.1 to 4.0; P = 0.025). While a poorer prognosis was observed in TNBC (n = 137) than in luminal BC patients (n = 496) (hazard ratio, 0.45; 95% CI, 0.30 to 0.68, P < 0.001), this aggressive nature of TNBC was noted in node-positive disease (hazard ratio, 0.3; 95% CI, 0.18 to 0.5, P < 0.001) but not in node-negative disease (hazard ratio, 0.78; 95% CI, 0.39 to 1.55, P = 0.472), and also noted in adipose tissue invasion-positive patients (hazard ratio, 0.4; 95% CI, 0.26 to 0.6, P < 0.001) but not in adipose tissue invasion-negative patients (hazard ratio, 0.73; 95% CI, 0.16 to 3.24, P = 0.675). In addition, although patients suffering from TNBC with adipose tissue invasion had a poorer outcome than those without adipose tissue invasion (hazard ratio, 3.63; 95% CI, 1.11 to 11.84; P = 0.033), the difference was not observed in luminal BC (hazard ratio, 1.75; 95% CI, 0.64 to 4.82; P = 0.277).

Conclusions

Adipose tissue invasion was correlated with poor survival in TNBC. Cancer cell invasion into local fat may be a first step on cancer progression and systemic disease in TNBC.

Cancer Biology

Oncology

Triple-negative breast cancer

Luminal breast cancer

Adipose tissue invasion

Tumor microenvironment

Patient survival

Obesity is a risk factor for many cancers including breast cancer (BC), but little is known about the relationship between cancer-cell invasion into local fat and patient survival in BC. The tumor microenvironment is a heterogeneous population of cells consisting of the tumor cells as well as endogenous stromal cells, such as vascular endothelial cells, pericytes, fibroblasts, bone-marrow mesenchymal stromal cells, immune cells and adipocytes ¹. These stromal cells are recruited by cancer cells and promote cellular migration, tumor angiogenesis, proliferation, invasion, and metastasis, as well as drug resistance ². Adipocytes are especially abundant stromal partners in breast tissue ³, and BC cell invasion into local fat seems to increase metastatic potential in the animal model ⁴.

Triple-negative breast cancer (TNBC) accounts for roughly 10–20% ^{5, 6} of all BC cases. The disease is viewed universally as the most devastating form of BC because of its aggressive nature ^{7, 8}. However, since there are still no markers to predict the efficacy of chemotherapy and well-defined molecular targets remain a topic of investigation⁹, current treatment options for TNBC commonly focus on cytotoxic chemotherapy. Although more aggressive chemotherapy has resulted in an improved prognosis, it usually leads to serious deterioration in quality of life.

On the other hand, we have observed in the clinical setting that TNBC patients do not present a uniformly dismal prognosis. We have also noticed a characteristic feature of survival outcome, that is, most of the recurrent disease occurs within a few years after surgery, and the recurrence risk rapidly decreases thereafter ^{6, 8}. Strikingly different from luminal BC, where more than half of recurrent disease occurs more than five years after surgery ^{10, 11}, this finding indicates the existence of TNBC patients who have a good prognosis without systemic disease as well as those who have a poor survival with residual disease after adjuvant chemotherapy ¹².

The present study aims to evaluate the significance of adipose tissue invasion on patient survival in luminal BC and TNBC. It is very important to explore the role of adipose tissue for cancer progression.

Patients

This retrospective study was approved by our institutional review board. We reviewed records from all patients with primary invasive carcinoma of the breast who underwent surgery between 1999 and 2014 at our institution (National Hospital Organization, Saga Hospital). Of the 858 patients, 123 were excluded for the following reasons: synchronous bilateral breast cancer (N = 28), metachronous bilateral breast cancer in the period (N = 9), clinically multifocal or multicentric cancers in the unilateral breast (N = 39), distant metastasis (N = 24), inflammatory carcinoma of the breast (N = 6), ipsilateral breast recurrence after breast-conserving surgery (N = 2), tissues inappropriate for histoloigical review due to preoperative neoadjuvant chemotherapy (N = 4), and patients who died within one year (N = 11). Thus, our final study population comprised 86% (735/858) of the total potential patients. All were women except one case. The patients were followed up until June 31, 2019, the median length of follow-up being 107 months (8.9 years) (range, 1-244 months) after surgery. Of the 735 patients in the current study, 472 (64%) had been included in our previous reports ¹³. This study did not involve the use of personal identifying information and individuals or families in the case of the deceased are not identified from data because of consecutive numbers of patients.

Survival analysis

The events used to determine the breast cancer-specific survival (BCSS) rate included death due to breast cancer. The overall survival (OS) rate included death due to breast cancer and other causes. The survival of the two groups in each analysis was compared in the entire group of patients and subgroups adjusted for clinical-pathological factors.

Tissue preparation and histological analyses

The resected breast and lymph node tissues were fixed in 10% formalin and the breast tissues were cut into 5-mm-thick slices ^{13, 14}. Each paraffin-embedded block was cut into 4-µm-thick sections and stained with hematoxylin and eosin. For the histological review, information on pathological tumor size, lymph node involvement (pN0: no regional lymph node metastasis, pN1: metastasis in 1 to 3 axillary ipsilateral lymph node, pN2: metastasis in 4–9 ipsilateral axillary lymph node, pN3: metastasis in 10 or more ipsilateral axillary lymph node), lymphatic vessel invasion, histological grade, adipose tissue invasion, hormone receptors (HR) status, and human epidermal growth factor receptor 2 (HER2) status was obtained from the prospective reports by pathologists (SA and KU, with 19 and 15 years of experience, respectively). The histological parameters between 1999 and 2009 were obtained from retrospective reviews conducted during the previous study by pathologists blinded to the survival outcome ¹³.

Definitions of adipose tissue and marginal adipose tissue invasion

Histological sections were obtained from the whole cut surface of the tumor at the maximal diameter. The definition of adipose tissue and marginal adipose tissue invasion followed that in our previous reports ^{13, 14}. Adipose tissue was defined as a pure aggregate consisting of more than 20 fat cells without intervening fibrous tissues in the breast. The adipose tissue included tissues surrounding the mammary ducts or lobules, as well as those in the subcutaneous layers. Furthermore, fibrous tissue and fibroadipose tissue (fat cells mixed with various fibrous tissues) around the terminal duct-lobular unit were strictly differentiated from adipose tissues. Marginal adipose tissue invasion was defined as either the presence of more than 20 cancer cells in direct contact with the adipose tissue or as the presence of cancer cells in the adipose tissue. Pathologists reviewing breast cancers have routinely reported on the presence or absence of adipose tissue invasion in their clinical reports since 1999 (1999–2014). Representative images of negative and positive adipose tissue invasion are shown in Fig. 1a and b, respectively.

Hormone receptor and HER2 status

Hormone receptor and HER2 status were evaluated as described previously ^13–15. Cases positive for estrogen receptor (ER) and progesterone receptor were defined as those with more than 10% of the cancer cell nuclei stained (ER-rich tumor). HER2 expression status was obtained on the basis of immunohistochemical analysis using commercially available antibodies. The intensity of HER2 staining was scored as follows: 0, 1+, 2+, or 3+. In the summary of results, we classified scores of 0 and 1 + as HER2 negative and scores of 3 + as HER2 positive. A HER2 score of 2 + was regarded as HER2-borderline and assessed by means of FISH assay.

Statistical analysis

Univariate analysis was carried out by Student t test, and χ² analysis. The prognostic difference between two groups (adipose tissue invasion-negative patients vs. adipose tissue invasion-positive patients and luminal BC vs. TNBC) were assessed by the univariate Cox-proportional hazard regression model. Survival curves were calculated using a Kaplan-Meier cumulative survival plot. Statistical analysis was conducted using the software StatView 5.0 for Mac (SAS Institute, Cary, NC). P < 0.05 was considered to indicate a statistically significant difference.

Clinical-pathologic parameters for patients with and without adipose tissue invasion, and prognostic outcome (BCSS, OS)

Of the 735 cases, 614 (84%) and 121 (16%) were patients with and without adipose tissue invasion, respectively. We compared the two groups (Table 1). Patient age and body mass index were similar in the two groups. Tumor size was significantly larger and the frequency of nodal involvement significantly higher in patients with adipose tissue invasion (P < 0.001 in both). Stage I (pathological classification) was observed much more frequently in patients without adipose tissue invasion, while stage II or III was observed much more frequently in patients with adipose tissue invasion. (P < 0.001). The frequency of lymphatic vessel invasion was significantly higher in patients with adipose tissue invasion (P < 0.001). On the other hand, a low histological grade (grade I and II) was observed much more frequently in patients with adipose tissue invasion, and a high histological grade (grade III) was observed much more frequently in patients without adipose tissue invasion (P = 0.019).

We compared survival outcome between the two groups. The results of overall analysis (all) and subgroup analysis are shown in Table 2. A poorer prognosis was observed among patients with adipose tissue invasion (N = 609) than among those without adipose tissue invasion (N = 119) in breast cancer-specific survival (BCSS) (hazard ratio, 3.23; 95% confidence interval [CI], 1.31 to 7.95; P = 0.010) and overall survival (OS) (hazard ratio, 2.1; 95% CI, 1.1 to 4.0; P = 0.025) in the entire group of patients (all). Then, we adjusted for age (< 70 and > = 70), pathological stage (I, II, III), and histologic grade (low grade and high grade) in OS. Patients with adipose tissue invasion showed a poorer rate of survival than those without adipose tissue invasion in the age of < 70 (hazard ratio, 2.69; 95% CI, 1.09 to 6.65; P = 0.032) and histologic high grade tumors (hazard ratio, 3.5; 95% CI, 1.27 to 9.67; P = 0.016).

Clinical-pathologic parameters and treatment in luminal BC and TNBC

Of the 735 cases, 502 (68%) were luminal BC (estrogen and progesterone receptors positive/human epidermal growth factor receptor type 2 negative; HR+/HER2-), 137 (19%) were TNBC (HR-/HER2-) and 59 (8%) were HER2-enriched BC (HR-/HER2+). The remaining 37 cases consisted of 29 HR+/HER2 + breast cancers (4%) and 8 unknown cases. Since the number of HER2-enriched BC cases was small and adjuvant one-year treatment with trastuzumab had been administered since 2009 (1999–2014), we compared the two tumor subtypes in this study, that is luminal BC and TNBC.

First, we compared clinical-pathological parameters between the two subtypes (Table 3). No difference was observed in either patient age (P = 0.429) or body mass index (P = 0.233). A statistically significant difference was observed in the pathologic tumor size (P = 0.008), but the frequency of lymph node involvement, stage and lymphatic vessel invasion was similar (P = 0.832, P = 0.403 and P = 0.259, respectively). Luminal BC was associated with a lower histological grade, while TNBC were associated with a higher histological grade (P < 0.001). With regard to adipose tissue invasion, the frequency of masses with adipose tissue invasion was higher in luminal BC cases, while the frequency of masses without adipose tissue invasion was higher in TNBC cases (P < 0.001).

Furthermore, we outlined the treatment administered for luminal BC and TNBC patients (Continued). No difference was observed among cases undergoing breast surgery, but the frequency of axillary lymph node dissection (ALND) was higher in TNBC patients (P = 0.002). Endocrine therapy was performed for 97% of luminal BC patients and for 23% of TNBC patients (P < 0.001). Endocrine therapy was indicated for tumors in which more than 1% of the cancer cell nuclei were stained. On the other hand, intravenous routine adjuvant chemotherapy (doxorubicin-cyclophosphamide, docetaxel-cyclophosphamide, epirubicin- cyclophosphamide, epirubicin-cyclophosphamide followed by paclitaxel, fluorouracil-epirubicin-cyclophosphamide followed by docetaxel, fluorouracil-doxorubicin-cyclophosphamide, docetaxel followed by epirubicin-cyclophosphamide) (ASCO Clinical Practice Guideline 2018 ¹⁶) was selected for 43% of luminal BC patients and for 75% of TNBC patients (P < 0.001). The median cycle of intravenous chemotherapy was four in luminal BC and six in TNBC. We usually establish the chemotherapy regimen (including no treatment) on the basis of the attending physician’s judgment, with reference to tumor size, lymph node status, overall performance status, presence or absence of medical comorbidities, and patient age. With regard to radiation therapy, no difference was observed between the two groups.

Comparison of survival outcome (OS) between luminal BC and TNBC

Next, we compared survival outcome between the two groups. The results of overall analysis and subgroup analysis are shown in Table 4. A poorer prognosis was observed among TNBC patients (n = 137) than among luminal BC patients (n = 496) in OS (hazard ratio, 0.45; 95% CI, 0.30 to 0.68, P < 0.001) in the entire group of patients (all). In subgroup analyses, a significantly poor outcome of TNBC was observed in the age (< 70 and > = 70) (P = 0.006 and P = 0.001, respectively), tumor size ( < = 2 cm and > 2 cm) (P = 0.005 and P = 0.016, respectively). On the other hand, no difference was observed in node-negative disease (hazard ratio, 0.78; 95% CI, 0.39 to 1.55, P = 0.472) (luminal BC and TNBC were 314 and 84 cases, respectively), but a marked difference was observed in node-positive disease (hazard ratio, 0.3; 95% CI, 0.18 to 0.5, P < 0.001) (176 and 45 cases, respectively) (also shown in Fig. 2a and b). With regard to stage, no difference was seen in stage I, but a significant difference was noted in stage II (P = 0.002) and III (P = 0.012). In addition, a poorer prognosis was observed among TNBC patients than among luminal BC patients in histologic low grade tumors (hazard ratio, 0.32; 95% CI, 0.18 to 0.59, P < 0.001), but the prognosis was similar in high grade tumors (P = 0.23). Moreover, although no difference was observed in adipose tissue invasion-negative patients (hazard ratio, 0.73; 95% CI, 0.16 to 3.24, P = 0.675) (luminal BC and TNBC were 54 and 35 cases, respectively), there was a remarkable difference in adipose tissue invasion-positive patients (hazard ratio, 0.4; 95% CI, 0.26 to 0.6, P < 0.001) (those were 442 and 102 cases, respectively) (Fig. 2c and d).

Prognostic outcome for patients with and without adipose tissue invasion in luminal BC and TNBC subtypes

We determined the prognosis of patients with and without adipose tissue invasion in the tumor subtypes. As shown in Table 5, no difference was observed in BCSS (hazard ratio, 1.75; 95% CI, 0.55 to 5.63; P = 0.346) or OS (hazard ratio, 1.75; 95% CI, 0.64 to 4.82; P = 0.277) when compared the cases of luminal BC with and without adipose tissue invasion (adipose tissue invasion-negative and adipose tissue invasion-positive cases were 54 and 442, respectively). On the other hand, we compared cases of TNBC with and without adipose tissue invasion. A significant differences was observed between the two groups in both BCSS (hazard ratio, 8.63; 95% CI, 1.17 to 63.66; P = 0.035) and OS (hazard ratio, 3.63; 95% CI, 1.11 to 11.84; P = 0.033) (those were 35 and 102, respectively). In TNBC, one of the patients without adipose tissue invasion died due to breast cancer diagnosed as node-positive disease at surgery.

Our study design focused on two tumor subtypes of BC (HR+/HER2- and HR-/HER2-) and defined cases with ER-rich tumors (more than 10% of the cancer cell nuclei stained) as hormone receptor-positive carcinoma. Furthermore, although this study is a single center review, we have made a sharp distinction between adipose tissue invasion-negative and adipose tissue invasion-positive BC. As a result, we obtained three valuable findings. First, tumors with adipose tissue invasion had a poorer prognosis than those without adipose tissue invasion in OS, as observed in high grade tumors. Second, although, as might be anticipated, TNBC showed a poorer survival than luminal BC, it was remarkable to find this to be the case in node-positive disease as well as adipose tissue invasion-positive patients. Third, patients suffering from TNBC with adipose tissue invasion had a poorer outcome than those without adipose tissue invasion, in contrast to luminal BC cases. Namely, it is likely that a poorer outcome of tumors with adipose tissue invasion was due to the cases of TNBC.

We reported previously that patients with adipose tissue invasion showed a poorer disease-free survival (DFS) than those without adipose tissue invasion ^{13, 14}. In the present study, the poor outcome was observed both in breast cancer-specific survival (BCSS) and, importantly, in OS. In addition, the results were found in TNBC patients. Marginal adipose tissue invasion resulted in marked cell changes in the course of tumor activity in TNBC. When we compared TNBC to luminal BC, we found that the poor survival of TNBC was seen in node-positive disease but not in node-negative disease and, therefore, that the highly aggressive nature of TNBC was due to lymph-node metastasis but not due to the tumor size or histological tumor grade in this study. Since adipose tissue invasion independently affected the nodal involvement in our previous study ¹⁴, it is suggested that the active behavior of adipose tissue invasion-positive TNBC is related to lymph-node metastasis.

Currently, the literature is scattered with studies on adipocyte biology in BC ^{1, 3}. Indeed, adipocytes are considered to constitute a critical cell type in the tumor microenvironment of BC ^{17, 18}. Recently, moreover, some investigators highlighted the striking effects of adipocytes on the human TNBC cell line, that is, enhanced cell migration and invasion ¹⁹. In the present study, it is suggested that nodal status is a very strong prognostic factor in TNBC. A relationship may exist between marginal adipose tissue invasion and the involvement of the functional lymphatic endothelium.

Meanwhile, a thoroughgoing estimation of a patient’s prognosis is crucial to avoid overtreatment and biological understanding helps us to escalate and de-escalate therapy even in high risk tumors ²⁰. In TNBC, few patients suffer recurrence between 5 and 10 years after surgery, and it is unlikely that chemotherapy exerts any major impact on late recurrence ²¹. We think that there is a group of patients whose disease is localized at the time of diagnosis. As shown in the results, of TNBC without adipose tissue invasion (n = 35) BC related-death was only one case. Although the confidence interval was very broad and the risk was unstable, most of adipose tissue invasion-negative TNBC seem to be localized disease. With regard to adjuvant management strategies, it is conceivable that the absolute benefit of chemotherapy is relatively small in those cases.

Tumors are composed of both cancer stem-like cells and other differentiated cancer cells ²². It has been proposed that the cancer stem-cell theory provides an insight into the aggressive nature of TNBC ¹². The TNBC phenotypes are highly similar to the cancer stem-cell phenotypes responsible for cancer progression, lymph node metastasis and distant metastasis as well as tumor initiation ^{12, 23}. In addition, accumulating evidence indicates that epithelial to mesenchymal transition shows similarities between the TNBC and cancer stem-cell phenotypes. It was reported that adipocytes from visceral white adipose tissue exert an enhanced effect on the epithelial to mesenchymal transition of BC cells ²⁴. There may be some relationship between cancer cell invasion into adipose tissue and expanding breast cancer stem cells in TNBC. Chemotherapy can eliminate the bulk of differentiated cancer cells but fail to eliminate breast cancer stem cells ²⁵.

The present study is limited in that it is an observational retrospective study, and it is relatively small in scale for an analysis of prognosis. Needless to say that triple negative breast cancers are heterogenous and encompass tumors with different histopathological features, but we have not been taken into account and classified TNBC cases with hormone receptor and HER2 status in this study. Moreover, tumor infiltrating lymphocytes (TILs) have been shown to exhibit a good prognosis in histologic screening, particularly in TNBC ²⁶. This might be useful for clinical decisions as a prognostic marker and should be included in pathology reports, but we have no data on the assessment of TILs.

In conclusion, cancer-cell invasion into local fat seems to change a tumor from “a silent bystander to an active facilitator ¹⁷” in TNBC. The next question is: Does adipose tissue invasion signal the start of the acquirement of malignant properties or the start of systemic disease in TNBC tumor cells?

BC: Breast cancer,

BCSS: breast cancer-specific survival,

CI; Confidence interval,

ER: estrogen receptor,

HR: hormone receptors,

HER2: human epidermal growth factor receptor 2, OS: overall survival,

TNBC : triple-negative breast cancer,

Availability of data and materials

All data (except for treatment data) generated or analysed for the current study are included in this supplementary information files. Treatment datasets will be available from the corresponding author on reasonable request.

Acknowledgement

We thank all the patients and associates who participated in this study.

Funding

There are none regarding funding.

Authors information

Affiliations

Department of Surgery, Fukuoka Seisyukai Hospital, Fukuoka, Japan

Junzo Yamaguchi, Takashi Ueda, Yujo Kawashita, Takanori Hazeyama and Masaki Tateishi　

Department of Surgery, National Hospital Organization, Saga Hospital, Saga, Japan

Hiroki Moriuchi

Department of Pathology and Microbiology, Faculty of Medicine, Saga University, Saga, Japan.

Shigehisa Aoki

Department of Pathology, National Hospital Organization, Saga Hospital, Saga, Japan

Kazuyoshi　Uchihashi

Department of Urology, Seisyukai Social Medical Corporation, Japan

Mikio Nakamura 　　　　

Authors’ contributions

JY and HM conceived the study design and analytical concept, and JY was a major contributor in writing the manuscript and critical revision of the manuscript. JY and YK performed statistical analyses and drafted the manuscript. HM, TU, YK, TH, and MT contributed to the acquisition of clinical patient informations. SA and KU contributed to the acquisition of pathology data. MN helped with data management and supported our work. All authors read and approved the final manuscript.

Corresponding author

Corresponding to Junzo Yamaguchi

Ethics declarations

Ethics approval and consent to participate

This retrospective study was approved by our institutional review board, and the requirement to obtain informed consent was waived for the retrospective study.

Ethics committee (name and number)

Ethical committee, National Hospital Organization, Saga Hospital (No 26-3)

Consent for publication

Not applicable.

Competing interests

The authors have declared no conflicts of interest.

Bussard KM, Mutkus L, Stumpf K, Gomez-Manzano C, Marini FC.Tumor-associated stromal cells as key contributors to the tumor microenvironment. Breast Cancer Res. 2016 Aug 11;18(1):84. doi: 10.1186/s13058-016-0740-2. PMID: 27515302

Hanahan D, Coussens LM: Accessories to the crime: functions of cells recruited to the tumor microenvironment. Cancer cell 2012 Mar 20;21(3):309-22.doi: 10.1016/j.ccr.2012.02.022. PMID: 22439926

Huang CK, Chang PH, Kuo WH, Chen CL, Jeng YM, Chang KJ, Shew JY, Hu CM, Lee WH.Adipocytes promote malignant growth of breast tumours with monocarboxylate transporter 2 expression via β-hydroxybutyrate. Nat Commun. 2017 Mar 10;8:14706. doi: 10.1038/ncomms14706.PMID: 28281525
Picon-Ruiz M, Pan C, Drews-Elger K, Jang K, Besser AH, Zhao D, Morata-Tarifa C, Kim M, Ince TA, Azzam DJ, Wander SA, Wang B, Ergonul B, Datar RH, Cote RJ, Howard GA, El-Ashry D, Torné-Poyatos P, Marchal JA, Slingerland JM. Interactions between Adipocytes andBreast Cancer Cells Stimulate Cytokine Production and Drive Src/Sox2/miR-302b-Mediated Malignant Progression. Cancer Res. 2016 Jan 15;76(2):491-504. doi: 10.1158/0008-5472.CAN-15-0927. Epub 2016 Jan 7. PMID: 26744520
Saraiva DP, Guadalupe Cabral M, Jacinto A, Braga S. How many diseases is triple negative breast cancer: the protagonism of the immune microenvironment. ESMO Open. 2017 Sep 14;2(4):e000208. doi: 10.1136/esmoopen-2017-000208. eCollection 2017.PMID: 29018573

Kumar P, Aggarwal R. An overview of triple-negative breast cancer. Arch Gynecol Obstet. 2016 Feb;293(2):247-69. doi: 10.1007/s00404-015-3859-y. Epub 2015 Sep 4.PMID: 26341644
Foulkes WD, Smith IE, Reis-Filho JS. Triple-negative breast cancer. N Engl J Med. 2010 Nov 11;363(20):1938-48. doi: 10.1056/NEJMra1001389.PMID: 21067385
Kast K, Link T, Friedrich K, Petzold A, Niedostatek A, Schoffer O, Werner C, Klug SJ, Werner A, Gatzweiler A, Richter B, Baretton G, Wimberger P. Impact of breastcancer subtypes and patterns of metastasis on outcome. Breast Cancer Res Treat. 2015 Apr;150(3):621-9. doi: 10.1007/s10549-015-3341-3. Epub 2015 Mar 18.PMID: 25783184
Xiao M, Lou C, Xiao H, Yang Y, Cai X, Li C, Jia S, Huang Y. MiR-128 regulation of glucose metabolism and cell proliferation in triple-negative breast cancer. Br J Surg. 2018 Jan;105(1):75-85. doi: 10.1002/bjs.10646. Epub 2017 Nov 8. PMID: 29116653

Sgroi DC, Sestak I, Cuzick J, Zhang Y, Schnabel CA, Schroeder B, Erlander MG, Dunbier A, Sidhu K, Lopez-Knowles E, Goss PE, Dowsett M. Prediction of late distant recurrence in patients with oestrogen-receptor-positive breast cancer: A prospective comparison of the breast-cancer index (BCI) assay, 21-gene recurrence score, and IHC4 in the TransATAC study population. Lancet Oncol. 2013 Oct;14(11):1067-1076. doi: 10.1016/S1470-2045(13)70387-5. Epub 2013 Sep 12.PMID: 24035531
Dubsky P, Brase JC, Jakesz R, Rudas M, Singer CF, Greil R, Dietze O, Luisser I, Klug E, Sedivy R, Bachner M, Mayr D, Schmidt M, Gehrmann MC, Petry C, Weber KE, Fisch K, Kronenwett R, Gnant M, Filipits M; Austrian Breast and Colorectal Cancer Study Group (ABCSG). The EndoPredict score provides prognostic information on late distant metastases in ER+/HER2- breast cancer patients. Br J Cancer. 2013 Dec 10;109(12):2959-64. doi: 10.1038/bjc.2013.671. Epub 2013 Oct 24.PMID: 24157828
Park SY, Choi JH, Nam JS: Targeting Cancer Stem Cells in Triple-Negative Breast Cancer. Cancers (Basel). 2019 Jul 9;11(7):965. doi: 10.3390/cancers11070965. PMID: 31324052
Moriuchi H, Yamaguchi J, Hayashi H, Ohtani H, Shimokawa I, Abiru H, Okada H, Eguchi S.Cancer Cell Interaction with Adipose Tissue: Correlation with the Finding of Spiculation at Mammography. Radiology. 2016 Apr;279(1):56-64. doi: 10.1148/radiol.2015142191. Epub 2015 Oct 9. PMID: 26458207
Yamaguchi J, Ohtani H, Nakamura K, Shimokawa I, Kanematsu T. Prognostic impact of marginal adipose tissue invasion in ductal carcinoma of the breast. Am J Clin Pathol. 2008 Sep;130(3):382-8. doi: 10.1309/MX6KKA1UNJ1YG8VN. PMID: 18701411
Kuba S, Ohtani H, Yamaguchi J, Hayashi H, Uga T, Kanematsu T, Shimokawa I. Incomplete inside-out growth pattern in invasive breast carcinoma: association with lymph vessel invasion and recurrence-free survival. Virchows Arch. 2011 Feb;458(2):159-69. doi: 10.1007/s00428-010-1033-2. Epub 2011 Jan 8. PMID: 21221635
Denduluri N, Chavez-MacGregor M, Telli ML, Eisen A, Graff SL, Hassett MJ, Holloway JN, Hurria A, King TA, Lyman GH, Partridge AH, Somerfield MR, Trudeau ME, Wolff AC, Giordano SH.J. Selection of Optimal Adjuvant Chemotherapy and Targeted Therapy for Early Breast Cancer: ASCO Clinical Practice Guideline Focused Update. Clin Oncol. 2018 Aug 10;36(23):2433-2443. doi: 10.1200/JCO.2018.78.8604. Epub 2018 May 22.PMID: 29787356
Choi J, Cha YJ, Koo JS: Adipocyte biology in breast cancer: From silent bystander to active facilitator. Prog Lipid Res. 2018 Jan;69:11-20. doi: 10.1016/j.plipres.2017.11.002. Epub 2017 Nov 21. PMID: 29175445
Pallegar NK, Christian SLAdipocytes in the Tumour Microenvironment. Adv Exp Med Biol. 2020;1234:1-13. doi: 10.1007/978-3-030-37184-5_1. PMID: 32040851
Nickel A, Blücher C, Kadri OA, Schwagarus N, Müller S, Schaab M, Thiery J, Burkhardt R, Stadler SC. Adipocytes induce distinct gene expression profiles in mammary tumor cells and enhance inflammatory signaling in invasive breast cancer cells. Sci Rep. 2018 Jun 21;8(1):9482. doi: 10.1038/s41598-018-27210-w. PMID: 29930291
Morigi C. Highlights from the 15th St Gallen International Breast Cancer Conference 15-18 March, 2017, Vienna: tailored treatments for patients with early breast cancer. 2017 Apr 7;11:732. doi: 10.3332/ecancer.2017.732. eCollection 2017. PMID: 28491135
Vaz-Luis I, Ottesen RA, Hughes ME, Mamet R, Burstein HJ, Edge SB, Gonzalez-Angulo AM, Moy B, Rugo HS, Theriault RL, Weeks JC, Winer EP, Lin NU. Outcomes by tumor subtype and treatment pattern in women with small, node-negative breast cancer: a multi-institutional study. J Clin Oncol. 2014 Jul 10;32(20):2142-50. doi: 10.1200/JCO.2013.53.1608. Epub 2014 Jun 2. PMID: 24888816
Kreso A, Dick JE. Evolution of the cancer stem cell model. Cell Stem Cell. 2014 Mar 6;14(3):275-91. doi: 10.1016/j.stem.2014.02.006. PMID: 24607403
Lee KL, Kuo YC, Ho YS, Huang YH. Triple-Negative Breast Cancer: Current Understanding and Future Therapeutic Breakthrough Targeting Cancer Stemness. Cancers. 2019 Sep 9;11(9):1334. doi: 10.3390/cancers11091334. PMID: 31505803

Ritter A, Friemel A, Fornoff F, Adjan M, Solbach C, Yuan J, Louwen F. Characterization of adipose-derived stem cells from subcutaneous and visceral adipose tissues and their function in breast cancer cells. 2015 Oct 27;6(33):34475-93. doi: 10.18632/oncotarget.5922. PMID: 26439686
Tominaga K, Minato H, Murayama T, Sasahara A, Nishimura T, Kiyokawa E, Kanauchi H, Shimizu S, Sato A, Nishioka K, Tsuji EI, Yano M, Ogawa T, Ishii H, Mori M, Akashi K, Okamoto K, Tanabe M, Tada KI, Tojo A, Gotoh N. Semaphorin signaling via MICAL3 induces symmetric cell division to expand breast cancer stem-like cells. Proc Natl Acad Sci U S A. 2019 Jan 8;116(2):625-630. doi: 10.1073/pnas.1806851116. Epub 2018 Dec 26. PMID: 30587593
Salgado R, Loi S. Tumour infiltrating lymphocytes in breast cancer: increasing clinical relevance. Lancet Oncol. 2018 Jan;19(1):3-5. doi: 10.1016/S1470-2045(17)30905-1. Epub 2017 Dec 7. PMID: 29233560

Due to technical limitations, table 1, 2, 3, 4 and 4 is only available as a download in the Supplemental Files section.

Download PDF

Journal Publication

published 20 Apr, 2021

Read the published version in BMC Cancer →

Editor assigned by journal
14 Dec, 2020
Submission checks completed at journal
14 Dec, 2020
Editor invited by journal
14 Dec, 2020
First submitted to journal
01 Dec, 2020

You are reading this latest preprint version

Active Behavior of Triple-Negative Breast Cancer With Adipose Tissue Invasion: A Single Center and Retrospective Review

Status:

Journal Publication

Version 1

Abstract

Figures

Background

Methods

Patients

Survival analysis

Tissue preparation and histological analyses

Definitions of adipose tissue and marginal adipose tissue invasion

Hormone receptor and HER2 status

Statistical analysis

Results

Clinical-pathologic parameters for patients with and without adipose tissue invasion, and prognostic outcome (BCSS, OS)

Clinical-pathologic parameters and treatment in luminal BC and TNBC

Comparison of survival outcome (OS) between luminal BC and TNBC

Discussion

Conclusions

Abbreviations

Declarations

References

Tables

Supplementary Files

Status:

Journal Publication

Version 1